These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20680368)

  • 1. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Ribes S; Pachón-Ibáñez ME; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1361-7. PubMed ID: 20680368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.
    Pachón-Ibáñez ME; Ribes S; Domínguez MA; Fernández R; Tubau F; Ariza J; Gudiol F; Cabellos C
    Eur J Clin Microbiol Infect Dis; 2011 Jan; 30(1):89-95. PubMed ID: 20844913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
    Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J
    Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides.
    Cabellos C; Garrigós C; Taberner F; Force E; Pachón-Ibañez ME
    J Infect Chemother; 2014 Sep; 20(9):563-8. PubMed ID: 24973908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models.
    LaPlante KL; Leonard SN; Andes DR; Craig WA; Rybak MJ
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2156-62. PubMed ID: 18411321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection.
    Yanagihara K; Kaneko Y; Sawai T; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3288-91. PubMed ID: 12234863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.
    Bal AM; Gould IM
    Expert Opin Pharmacother; 2005 Oct; 6(13):2257-69. PubMed ID: 16218886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit model.
    Calik S; Turhan T; Yurtseven T; Sipahi OR; Buke C
    Med Sci Monit; 2012 Nov; 18(11):SC5-8. PubMed ID: 23111752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptides.
    Giacometti A; Ghiselli R; Cirioni O; Mocchegiani F; Orlando F; Del Prete MS; D'Amato G; Silvestri C; Saba V; Scalise G
    J Antimicrob Chemother; 2003 Oct; 52(4):724-6. PubMed ID: 12951347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Park HJ; Kim SH; Kim MJ; Lee YM; Park SY; Moon SM; Park KH; Chong YP; Lee SO; Choi SH; Woo JH; Kim YS
    J Infect; 2012 Dec; 65(6):505-12. PubMed ID: 22902942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
    Jacqueline C; Batard E; Perez L; Boutoille D; Hamel A; Caillon J; Kergueris MF; Potel G; Bugnon D
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3706-11. PubMed ID: 12435665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection.
    Baldoni D; Haschke M; Rajacic Z; Zimmerli W; Trampuz A
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1142-8. PubMed ID: 19075065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
    Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.